NIH on menopause treatments
This article was originally published in The Tan Sheet
Executive Summary
"There are major methodological problems associated with studying products that are not standardized, [and as a result] the study of botanicals as treatments for hot flashes is still in its infancy," an independent panel convened by NIH says in a March 23 report. The group recommends dosing, mechanisms of action and metabolic processes of botanicals be established in order for research to "move forward on a solid foundation"...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.